SLE (n=75) | RA (n=75) | Controls (n=75) | |
Women | 88 | 88 | 88 |
Age (y) | 45 (20–70) | 45 (22–70) | 45 (20–70) |
White | 100 | 100 | 100 |
Disease duration (y) | 8.1 (2–27) | 7.9 (2–26) | NA |
Body mass index | 23.5 (17.7–37.6) | 23.4 (16.6–36.5) | 24.0 (18.7–36.3) |
Smokers (current or previous) | 68 | 63 | 56 |
Menopause | 43 | 32 | 31 |
Oestrogen replacement therapy | |||
Ever users | 24 | 24 | 20 |
Current users | 19 | 19 | 19 |
Osteoporotic fractures | 11 | 3 | 4 |
MHAQ | 1.32 (1.0–3.00)1-150 | 1.53 (1.0–2.75) | 1.07 (1.0–1.88)** |
SF-36 physical | 66.8 (5–100)1-150 | 57.5 (0–100) | 89.7 (20–100)** |
SLEDAI | 6.93 (0–24) | NA | NA |
SDI | 2.07 (0–13) | NA | NA |
Tender joints | 3.2 (0–28)1-150 | 6.1 (0–23) | NA |
Swollen joints | 2.0 (0–21)1-150 | 7.3 (0–23) | NA |
Corticosteroids | |||
Ever users | 851-150 | 64 | 0 |
Current users | 60 | 45 | 0 |
Mean current dose | 7.4 (2.5–20) | 6.6 (2.5–20) | NA |
Cumulative dose (g) | 21.8 (0.23–113.4)1-150 | 11.8 (0–75.6) | NA |
Duration, months | 72.6 (1–364) | 52.2 (0–336) | NA |
Current NSAIDs | 171-150 | 44 | NA |
Current DMARDs | 35 | 32 | NA |
Current cytotoxic drugs | 19 | 29 | NA |
↵1-150 p<0.05 SLE v RA. **p<0.001 SLE and RA v healthy controls. NA : not applicable, MHAQ : Modified Health Assessment Questionnaire, SLEDAI : SLE Disease Activity Index, SDI : Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, NSAID : non-steroidal anti-inflammatory drug, DMARD : disease modifying antirheumatic drug.